LY011

LY011 is a chimeric antigen receptor (CAR) T-cell therapy targeting the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2). It is being developed for the treatment of advanced gastric adenocarcinoma and pancreatic cancer. The therapy involves T lymphocytes that have been genetically modified to express a CAR that specifically targets CLDN18.2, which is expressed in certain solid tumors. This allows the modified T cells to recognize and attack cancer cells expressing this antigen.

Other names

anti-CLDN18.2 CAR T cells LY011anti-CLDN-18.2 CAR T cells LY011anti-CLDN 18.2 CAR T cells LY011CLDN 18.2 CAR-T cell therapyCLDN18.2 CAR-T cell therapyCLDN-18.2 CAR-T cell therapy